Literature DB >> 27821617

Increased Notch3 Activity Mediates Pathological Changes in Structure of Cerebral Arteries.

Celine Baron-Menguy1, Valérie Domenga-Denier1, Lamia Ghezali1, Frank M Faraci1, Anne Joutel2.   

Abstract

CADASIL (Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy), the most frequent genetic cause of stroke and vascular dementia, is caused by highly stereotyped mutations in the NOTCH3 receptor, which is predominantly expressed in vascular smooth muscle. The well-established TgNotch3R169C mouse model develops characteristic features of the human disease, with deposition of NOTCH3 and other proteins, including TIMP3 (tissue inhibitor of metalloproteinase 3), on brain vessels, as well as reduced maximal dilation, and attenuated myogenic tone of cerebral arteries, but without elevated blood pressure. Increased TIMP3 levels were recently shown to be a major determinant of altered myogenic tone. In this study, we investigated the contribution of TIMP3 and Notch3 signaling to the impairment of maximal vasodilator capacity caused by the archetypal R169C mutation. Maximally dilated cerebral arteries in TgNotch3R169C mice exhibited a decrease in lumen diameter over a range of physiological pressures that occurred before myogenic tone deficits. This defect was not prevented by genetic reduction of TIMP3 in TgNotch3R169C mice and was not observed in mice overexpressing TIMP3. Knock-in mice with the R169C mutation (Notch3R170C/R170C) exhibited similar reductions in arterial lumen, and both TgNotch3R169C and Notch3R170C/R170C mice showed increased cerebral artery expression of Notch3 target genes. Reduced maximal vasodilation was prevented by conditional reduction of Notch activity in smooth muscle of TgNotch3R169C mice and mimicked by conditional activation of Notch3 in smooth muscle, an effect that was blood pressure-independent. We conclude that increased Notch3 activity mediates reduction in maximal dilator capacity of cerebral arteries in CADASIL and may contribute to reductions in cerebral blood flow.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  CADASIL; Notch3 protein, mouse; cerebral small vessel diseases; stroke; vasodilation

Mesh:

Substances:

Year:  2016        PMID: 27821617      PMCID: PMC5145742          DOI: 10.1161/HYPERTENSIONAHA.116.08015

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  31 in total

1.  CADASIL Notch3 mutant proteins localize to the cell surface and bind ligand.

Authors:  Talin Haritunians; Jim Boulter; Carol Hicks; Jonathon Buhrman; Guy DiSibio; Carrie Shawber; Gerry Weinmaster; Donna Nofziger; Carolyn Schanen
Journal:  Circ Res       Date:  2002-03-22       Impact factor: 17.367

2.  Notch3 is required for arterial identity and maturation of vascular smooth muscle cells.

Authors:  Valérie Domenga; Peggy Fardoux; Pierre Lacombe; Marie Monet; Jacqueline Maciazek; Luke T Krebs; Bernard Klonjkowski; Eliane Berrou; Matthias Mericskay; Zhen Li; Elisabeth Tournier-Lasserve; Thomas Gridley; Anne Joutel
Journal:  Genes Dev       Date:  2004-11-15       Impact factor: 11.361

Review 3.  The canonical Notch signaling pathway: unfolding the activation mechanism.

Authors:  Raphael Kopan; Maria Xenia G Ilagan
Journal:  Cell       Date:  2009-04-17       Impact factor: 41.582

4.  Potassium channelopathy-like defect underlies early-stage cerebrovascular dysfunction in a genetic model of small vessel disease.

Authors:  Fabrice Dabertrand; Christel Krøigaard; Adrian D Bonev; Emmanuel Cognat; Thomas Dalsgaard; Valérie Domenga-Denier; David C Hill-Eubanks; Joseph E Brayden; Anne Joutel; Mark T Nelson
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

Review 5.  Ligand-Independent Mechanisms of Notch Activity.

Authors:  William Hunt Palmer; Wu-Min Deng
Journal:  Trends Cell Biol       Date:  2015-10-01       Impact factor: 20.808

Review 6.  Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges.

Authors:  Leonardo Pantoni
Journal:  Lancet Neurol       Date:  2010-07       Impact factor: 44.182

7.  Distinct phenotypic and functional features of CADASIL mutations in the Notch3 ligand binding domain.

Authors:  Marie Monet-Leprêtre; Boris Bardot; Barbara Lemaire; Valérie Domenga; Ophélia Godin; Martin Dichgans; Elisabeth Tournier-Lasserve; Michel Cohen-Tannoudji; Hugues Chabriat; Anne Joutel
Journal:  Brain       Date:  2009-03-17       Impact factor: 13.501

8.  Mechanics of large and small cerebral arteries in chronic hypertension.

Authors:  M A Hajdu; G L Baumbach
Journal:  Am J Physiol       Date:  1994-03

9.  Pathogenic mutations associated with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy differently affect Jagged1 binding and Notch3 activity via the RBP/JK signaling Pathway.

Authors:  Anne Joutel; Marie Monet; Valérie Domenga; Florence Riant; Elisabeth Tournier-Lasserve
Journal:  Am J Hum Genet       Date:  2004-01-08       Impact factor: 11.025

10.  Transcriptome analysis for Notch3 target genes identifies Grip2 as a novel regulator of myogenic response in the cerebrovasculature.

Authors:  Charles Fouillade; Céline Baron-Menguy; Valérie Domenga-Denier; Christelle Thibault; Kogo Takamiya; Richard Huganir; Anne Joutel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-11-01       Impact factor: 8.311

View more
  17 in total

Review 1.  Contributions of Aging to Cerebral Small Vessel Disease.

Authors:  T Michael De Silva; Frank M Faraci
Journal:  Annu Rev Physiol       Date:  2019-10-16       Impact factor: 19.318

Review 2.  Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke.

Authors:  Xiaoming Hu; T Michael De Silva; Jun Chen; Frank M Faraci
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

3.  Early-Onset Vascular Leukoencephalopathy Caused by Bi-Allelic NOTCH3 Variants.

Authors:  Menno D Stellingwerff; Corinne Nulton; Guy Helman; Stefan D Roosendaal; William S Benko; Amy Pizzino; Marianna Bugiani; Adeline Vanderver; Cas Simons; Marjo S van der Knaap
Journal:  Neuropediatrics       Date:  2022-02-23       Impact factor: 1.696

4.  HB-EGF depolarizes hippocampal arterioles to restore myogenic tone in a genetic model of small vessel disease.

Authors:  Jackson T Fontaine; Amanda C Rosehart; Anne Joutel; Fabrice Dabertrand
Journal:  Mech Ageing Dev       Date:  2020-10-27       Impact factor: 5.432

Review 5.  Notch3 Signaling and Aggregation as Targets for the Treatment of CADASIL and Other NOTCH3-Associated Small-Vessel Diseases.

Authors:  Dorothee Schoemaker; Joseph F Arboleda-Velasquez
Journal:  Am J Pathol       Date:  2021-04-22       Impact factor: 4.307

Review 6.  CADASIL from Bench to Bedside: Disease Models and Novel Therapeutic Approaches.

Authors:  Arianna Manini; Leonardo Pantoni
Journal:  Mol Neurobiol       Date:  2021-01-19       Impact factor: 5.590

7.  Therapeutic antibody targeting of Notch3 signaling prevents mural cell loss in CADASIL.

Authors:  Arturo I Machuca-Parra; Alexander A Bigger-Allen; Angie V Sanchez; Anissa Boutabla; Jonathan Cardona-Vélez; Dhanesh Amarnani; Magali Saint-Geniez; Christian W Siebel; Leo A Kim; Patricia A D'Amore; Joseph F Arboleda-Velasquez
Journal:  J Exp Med       Date:  2017-07-11       Impact factor: 14.307

8.  Exome sequencing study revealed novel susceptibility loci in subarachnoid hemorrhage (SAH).

Authors:  Xiwa Hao; Jiangxia Pang; Ruiming Li; Lin Lv; Guorong Liu; Yuechun Li; Guojuan Cheng; Jingfen Zhang
Journal:  Mol Brain       Date:  2020-05-25       Impact factor: 4.041

9.  Effects of Cerebral Blood Flow and White Matter Integrity on Cognition in CADASIL Patients.

Authors:  Xinzhen Yin; Ying Zhou; Shenqiang Yan; Min Lou
Journal:  Front Psychiatry       Date:  2019-01-14       Impact factor: 4.157

Review 10.  Genetics of Cerebral Small Vessel Disease.

Authors:  Sandro Marini; Christopher D Anderson; Jonathan Rosand
Journal:  Stroke       Date:  2019-11-22       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.